Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Melinda Charrier"'
Autor:
Petros Tsantoulis, Yann Christinat, Prasad Chaskar, Liza Ho, Sophie Clément, Melinda Charrier, Thomas Alexander Mckee
Publikováno v:
The Journal of Molecular Diagnostics. 23:1722-1731
Copy number alterations are genetic events that promote tumor initiation and progression and are used in clinical care as diagnostic, prognostic, and predictive biomarkers. Based on the length of the alteration, they are roughly classified as focal a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec234b5a74a474a33537e878b6057a0
https://doi.org/10.1016/j.jmoldx.2021.08.003
https://doi.org/10.1016/j.jmoldx.2021.08.003
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a96c55a9d472fb0598bd6fb82e8dace
https://doi.org/10.1016/j.ejca.2021.03.011
https://doi.org/10.1016/j.ejca.2021.03.011
Autor:
Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin
Publikováno v:
Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c882e2c41b9625dab34c1f829ff27
https://doi.org/10.1080/15384047.2019.1685291
https://doi.org/10.1080/15384047.2019.1685291
Autor:
Mélanie Desbois, Coralie Béal, Lydie Cassard, Guillaume Meurice, Yannick Jacques, Melinda Charrier, Nathalie Chaput, Benjamin Besse, Nicolas Cagnard, David Bechard
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2019, 8 (1), pp.e000632. ⟨10.1136/jitc-2020-000632⟩
Journal for Immunotherapy of Cancer, 2019, 8 (1), pp.e000632. ⟨10.1136/jitc-2020-000632⟩
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2019, 8 (1), pp.e000632. ⟨10.1136/jitc-2020-000632⟩
Journal for Immunotherapy of Cancer, 2019, 8 (1), pp.e000632. ⟨10.1136/jitc-2020-000632⟩
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundAs the immune system is compromised in patients with cancer, therapeutic strategies to stimulate immunity appear promising, to avoid relapse and increase long-term overall survival. Interleukin-15 (IL-15) has similar properties to IL-2, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c5219d7e0439186e97e8152f4071b19
https://www.hal.inserm.fr/inserm-03498336
https://www.hal.inserm.fr/inserm-03498336
Autor:
Mauro Frigeri, Alexandre Bodmer, Krisztian Homicsko, Jean-Christophe Tille, Olivier Michielin, Thomas Alexander Mckee, Yann Christinat, Petros Tsantoulis, Laure Thouvenin, Sophie Clément, Pierre O. Chappuis, Melinda Charrier
Publikováno v:
Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 37, Iss, Pp 100787-(2021)
Gynecologic oncology reports, vol. 37, pp. 100787
Gynecologic Oncology Reports, Vol. 37 (2021) P. 100787
Gynecologic Oncology Reports, Vol 37, Iss, Pp 100787-(2021)
Gynecologic oncology reports, vol. 37, pp. 100787
Gynecologic Oncology Reports, Vol. 37 (2021) P. 100787
Highlights • Trastuzumab monotherapy has limited efficacy in ovarian cancer. • The combination of trastuzumab and pertuzumab has not been studied adequately. • An ERBB2-amplified ovarian carcinoma had a durable response to this combination. •
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c295064b33afba194517ef22e0972280
https://doi.org/10.1016/j.gore.2021.100787
https://doi.org/10.1016/j.gore.2021.100787
Autor:
Daniele, Frisone, Melinda, Charrier, Sophie, Clement, Yann, Christinat, Laure, Thouvenin, Krisztian, Homicsko, Olivier, Michielin, Alexandre, Bodmer, Pierre O, Chappuis, Thomas A, McKee, Petros, Tsantoulis
Publikováno v:
Cancer Biology & Therapy
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55f252a2da5798695f6662492f9a52ae
https://pubmed.ncbi.nlm.nih.gov/31709901
https://pubmed.ncbi.nlm.nih.gov/31709901
Autor:
Pilar Garrido, Roberto Ferrara, Clarisse Audigier-Valette, Jordi Remon, Melinda Charrier, Jorge Zeron-Medina, L. Arés, L. Leroy, Julien Mazieres, Solenn Brosseau, J. Lahmar, Jean-Charles Soria, Caroline Caramela, Edouard Auclin, Enriqueta Felip, Santiago Ponce, David Planchard, Laura Mezquita, Gérard Zalcman, Nathalie Chaput, Julien Adam, Benjamin Besse
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma.To determine whether pretreatment dNLR and LDH are as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72cd7fdbc3137d2c1ce8ca455977f45
https://pubmed.ncbi.nlm.nih.gov/29849197
https://pubmed.ncbi.nlm.nih.gov/29849197
Autor:
Boris Duchemann, David Planchard, Maud Ngo-Camus, Melinda Charrier, Lydie Cassard, Patricia Martin-Romano, Edouard Auclin, I. Gataa, Laura Mezquita, Roberto Ferrara, Nathalie Chaput, L. Boselli, Julien Adam, M. Naigeon, Jonathan Grivel, Benjamin Besse
Publikováno v:
Journal of Thoracic Oncology. 14:S272-S273
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a62e4eb6ac9256bcc3fbdb9b0de6f849
https://doi.org/10.1016/j.jtho.2019.08.547
https://doi.org/10.1016/j.jtho.2019.08.547
Autor:
Anas Gazzah, Louise Dupraz, Jean-Charles Soria, Jordi Remon, Jean Pierre Pignon, Francesco Facchinetti, Julien Adam, Valentina Polo, Arslane Skander Rahal, Caroline Caramella, Béranger Lueza, Melinda Charrier, Nathalie Chaput, Benjamin Besse, Laura Mezquita, Laura Faivre, Maria Bluthgen, David Planchard
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Introduction The class I human leucocyte antigen (HLA) molecules play a critical role as an escape mechanism of antitumoral immunity. HLA-A2 status has been evaluated as a prognostic factor in lung cancer, mostly in localized disease and with inconsi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::536a3204ee7da18c0e00eaefec36cc2a
https://pubmed.ncbi.nlm.nih.gov/29191581
https://pubmed.ncbi.nlm.nih.gov/29191581
Autor:
Emilie Soularue, Melinda Charrier, Antoine Racine, Christine Mateus, Clélia Coutzac, Lydie Cassard, Nyam Kamsu-Kom, Karim Fizazi, Patricia Lepage, Nathalie Chaput, L. Boselli, Charlotte Mussini, Michael Collins, Yohann Loriot, Caroline Robert, Jean-Yves Scoazec, Julien Adam, Franck Carbonnel, Vincent Ribrag, David Planchard
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2017, 11 (10), pp.1238-1246. ⟨10.1093/ecco-jcc/jjx081⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2017, 11 (10), pp.1238-1246. ⟨10.1093/ecco-jcc/jjx081⟩
International audience; Background and Aim: Immune checkpoint inhibitors targeting CTLA-4 and PD-1 improve survival in cancer patients but may induce immune-related adverse events, including colitis. The immunological characteristics of anti-CTLA-4 [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd05e6fbe3fbc8994d8bbaa19ad41fc
https://hal.inrae.fr/hal-02625648
https://hal.inrae.fr/hal-02625648